MeiraGTx Holdings plc
MeiraGTx Holdings plc
Your view on MGTX
Overview
What the company does, where it operates, and who runs it.
About MeiraGTx Holdings plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alexandria Forbes
- Headquarters
- 430 East 29th Street, New York City, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alexandria Forbes
- Headquarters
- 430 East 29th Street, New York City, NY, US
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases.
Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program.
The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology.
MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for MeiraGTx Holdings plc, and the rating behind it. MGTX last traded at $9.18, 12.1× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for MeiraGTx Holdings plc. Starting points for MeiraGTx Holdings plc: P/E 12.1, EPS $0.86, beta 1.35 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for MeiraGTx Holdings plc. MeiraGTx Holdings plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for MeiraGTx Holdings plc. Trailing twelve-month EPS for MeiraGTx Holdings plc stands at $0.86. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for MeiraGTx Holdings plc. MeiraGTx Holdings plc has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
MeiraGTx Holdings plc valued side by side against its closest peers. MeiraGTx Holdings plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold MeiraGTx Holdings plc, and how their positions are changing. At a $881.7M market value, institutional positions materially move MeiraGTx Holdings plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by MeiraGTx Holdings plc executives and directors. Shares of MeiraGTx Holdings plc have traded between $4.55 and $9.73 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming MeiraGTx Holdings plc. MeiraGTx Holdings plc is a $881.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming MeiraGTx Holdings plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for MeiraGTx Holdings plc. Coverage tracks MeiraGTx Holdings plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.